Ophthalmic Microneedle Patch With PVA for Corneal Drug Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Commercial sodium hyaluronate eye drops with a concentration of 0.1% have poor therapeutic effects on severe corneal wounds due to short ocular surface retention time, poor corneal barrier penetration, and poor patient compliance, leading to inflammation and potential blindness.
Innovation Solution
A sodium hyaluronate-containing ophthalmic microneedle patch is prepared by mixing sodium hyaluronate with polyvinyl alcohol (PVA) to enhance mechanical properties, allowing for effective corneal penetration and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium hyaluronate eye drops with 0.1% concentration are used, then the formulation is simple and safe for mild corneal wounds, but the therapeutic effect is poor for severe corneal wounds due to short ocular surface retention time and poor corneal barrier penetration
Solution Approach 1:
The patent changes the concentration parameter of sodium hyaluronate from 0.1% to 0.3%, and transforms the dosage form from liquid eye drops to microneedle patches. This parameter change increases the drug loading amount and enables sustained release, thereby extending ocular surface retention time and improving therapeutic effect for severe corneal wounds
Solution Approach 2:
The patent introduces polyvinyl alcohol (PVA) as a matrix material to form microneedle patches. PVA serves as an intermediary carrier that enables controlled release of sodium hyaluronate, extending its retention time on the ocular surface and improving corneal barrier penetration through the microneedle delivery system
2Reliability
If commercial eye drops are used frequently to treat severe corneal wounds, then the ocular surface is continuously exposed to the drug, but patient compliance is poor due to frequent dropping requirements
Solution Approach 1:
The patent loads a high concentration of sodium hyaluronate (0.3%) into microneedle patches in advance, creating a reservoir of drug that releases slowly over time. This preliminary action eliminates the need for frequent application, improving patient compliance while maintaining continuous therapeutic effect for severe corneal wounds
Solution Approach 2:
The microneedle patches are designed as disposable single-use devices. Each patch contains sufficient drug loading to treat severe corneal wounds without requiring repeated applications, simplifying the treatment regimen and improving patient compliance
3Ease of manufacture
If sodium hyaluronate is used to prepare microneedle patches alone, then the formulation is simple, but the needle formation rate is low and the hardness is insufficient
Solution Approach 1:
The patent creates a composite matrix system by combining sodium hyaluronate (0.3%) with polyvinyl alcohol (PVA). This composite material approach maintains formulation simplicity while significantly improving needle formation rate and mechanical hardness, enabling successful microneedle patch manufacturing
4Ease of manufacture
If sodium hyaluronate is used to prepare microneedle patches alone, then the formulation is simple, but the mechanical strength and flexibility are insufficient
Solution Approach 1:
The patent develops a composite matrix comprising sodium hyaluronate and PVA in specific ratios. This composite material provides both mechanical strength for needle integrity and flexibility for comfortable ocular application, while keeping the formulation process simple and scalable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microneedle patch demonstrates strong mechanical properties, flexibility, and efficient delivery of sodium hyaluronate to the corneal tissue, effectively treating severe corneal wounds and reducing inflammation.
Implementation Method 1
Because carboxyl and hydroxyl groups in a molecular structure of sodium hyaluronate can form hydrogen bonds with water, sodium hyaluronate exhibits excellent water-retention properties
Implementation Method 2
Microneedles are a minimally-invasive and painless drug delivery manner with a length of 25 μm to 2,000 μm, which can effectively break the physical barrier of a tissue and efficiently deliver a drug to a target site
Implementation Method 3
Sodium hyaluronate eye drops can bind to fibronectin to enhance the adhesion and extensibility of corneal epithelial cells and improve the self-repair ability of corneas
Data Source
AI summary
Provided is a sodium hyaluronate-containing ophthalmic microneedle patch, and a preparation method and use thereof. The preparation method includes: preparing a microneedle patch matrix solution, where the microneedle patch matrix solution includes sodium hyaluronate and polyvinyl alcohol (PVA); and dropping the microneedle patch matrix solution into a microneedle patch mold, drying, and then demolding to obtain the sodium hyaluronate-containing ophthalmic microneedle patch.